ClinicalTrials.gg
CompletedNCT06281470Updated Feb 28, 2024

The Safety and Tolerability of WS016 in Healthy Chinese Volunteers

A Phase 1 interventional study of WS016 Single Dose(6g) and WS016 Single Dose(12g) in Hyperkalemia, sponsored by Waterstone Pharmaceutical (Wuhan) Co., LTD.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Waterstone Pharmaceutical (Wuhan) Co., LTD. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hyperkalemia with a site in China — 7 open to participants now, 8 under way, 3 of them phase 3. Hyperkalemia · China.

Enrollment
12th of 13
66 · median 270
Started
2023
with 1 other
Phase 1
Only one
of the 20
Registered
15th of 20
by date
Lead sponsor
4 of 20
Waterstone Pharmaceutical (Wuhan) Co., LTD.

Among the 20 studies in Hyperkalemia with a site in China, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1, and was the 15th registered.

Hyperkalemia

133 studies on the registry are indexed under Hyperkalemia; 25 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

7 of the 20 studies in Hyperkalemia with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 15 Hyperkalemia studies recruiting now, 10 (67%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hyperkalemia with a site in China, or all of them as a file.
02

Study summary

This clinic trial evaluates the safety and tolerability of single- and multiple- ascending doses of WS016 in healthy adult participants. There will be about 64 participants,48 active and 16 placebo.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participants are fully informed of the purpose, methods and possible adverse reactions of the trial, and volunteer to serve as participants. And participants sign the form before any research procedures begin;
  2. Participants are healthy male or female volunteers between the ages of 18 and 45 (including the cut-off values);
  3. The weight of male participants is ≥50 kg, and the weight of female participants is ≥45 kg with a (BMI) of 19.0\~26.0 kg/m\^2 (including boundary values, BMI=weight (kg)/height\^2 (m\^2));
  4. The participants understand and comply with the study procedures, can communicate well with the researchers, volunteer to participate in the trial, and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a specific allergy history (asthma, urticaria, eczema, etc.) or allergic constitution (e.g., known allergies to two or more substances), or known prior allergy to WS016 and related ;
  2. Participants with chronic diseases or severe diseases in the liver, kidney, digestive system, endocrine system, cardiovascular system, nervous system, metabolic system, blood system, respiratory system, and system, or current diseases in these systems as judged by investigators to be unsuitable for inclusion;
  3. Participants who have undergone surgery within 3 months prior to screening, or plan to undergo surgery during the study period, as well as subjects who have undergone surgery that affects drug absorption, distribution, metabolism, and excretion;
  4. Participants with dysphagia or gastrointestinal diseases/symptoms judged by investigators to affect drug absorption;
  5. Participants who have received blood transfusions or used blood products ≥400 mL or 2 units within 3 months prior to screening, or have lost ≥400 mL of blood within 6 months, or have donated blood within 3 months;
  6. Participants who have used any prescription drugs (including vaccines), over-the-counter drugs within 4 weeks prior to screening;
  7. Pregnant or breastfeeding women, or participants with positive pregnancy test results before screening; male participants (or their partners) or female participants who have plans for pregnancy, sperm donation plans, or egg donation plans from the time they sign the form until 6 months after dosing; participants who are unwilling to use a medically recognized non-drug method (e.g., intrauterine device or condom) during the study period;
  8. Participants with abnormal findings in physical examination, vital signs examination, , laboratory tests (including blood routine, urine routine, blood biochemistry, coagulation function), abdominal B-mode ultrasound examination, chest X-ray examination as judged by investigators to be ;
  9. Participants with positive results for surface antigen (HBsAg), virus (HCV) quantitative test, (HIV) quantitative test, and syphilis antibody test;
  10. Participants with a history of drug abuse within 12 months before screening, or urine drug screening positive results;
  11. Participants with positive results in alcohol breath testing, or participants who consume alcohol regularly within 3 months before screening (defined as an average of more than 14 units of alcohol per week, and 1 unit is approximately equal to 200 mL of beer with a 5% alcohol content, or 25 mL of strong liquor with a 40% alcohol content, or 85 mL of wine with a 12% alcohol content), or participants who cannot abstain from alcohol during the study period;
  12. Participants who are considered unsuitable for participation in this study by investigators.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose(SAD) Treatment 1

    WS016 single dose(6g)

    Drug: WS016 Single Dose(6g)

  • Experimental
    SAD Treatment 2

    WS016 single dose(12g)

    Drug: WS016 Single Dose(12g)

  • Experimental
    SAD Treatment 3

    WS016 single dose(24g)

    Drug: WS016 Single Dose(24g)

  • Experimental
    SAD Treatment 4

    WS016 single dose(36g)

    Drug: WS016 Single Dose(36g)

  • Experimental
    SAD Treatment 5

    WS016 single dose(48g)

    Drug: WS016 Single Dose(48g)

  • Placebo comparator
    SAD matching placebo

    SAD Matching placebo

    Drug: SAD matching placebo

  • Experimental
    Multiple Ascending Dose(MAD) Treatment 1

    WS016 multiple dose(MAD Low Dose)

    Drug: WS016 Multiple Dose(12g)

  • Experimental
    MAD Treatment 2

    WS016 multiple dose(MAD Medium Dose)

    Drug: WS016 Multiple Dose(24g)

  • Experimental
    MAD Treatment 3

    WS016 multiple dose(MAD High Dose)

    Drug: WS016 Multiple Dose(48g)

  • Placebo comparator
    MAD matching placebo

    MAD matching placebo

    Drug: MAD matching placebo

Interventions

  • WS016 6g, to be administered orally as a single dose.

  • WS016 12g, to be administered orally as a single dose.

  • WS016 24g, to be administered orally as a single dose.

  • WS016 36g, to be administered orally as a single dose.

  • WS016 48g, to be administered orally as a single dose.

  • DrugSAD matching placebo

    Matching placebo, to be administered orally as a single dose.

  • WS016 12g, to be administered orally once daily for a consecutive period of 7 days.

  • WS016 24g, to be administered orally once daily for a consecutive period of 7 days.

  • WS016 48g, to be administered orally once daily for a consecutive period of 7 days.

  • DrugMAD matching placebo

    Matching placebo, to be administered orally once daily for a consecutive period of 7 days.

06

What researchers measure

Primary outcomes

  1. Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single- and multiple- ascending dose

    Incidence, severity and causality of AEs and SAEs

    Time frame: up to Day 17

07

Study locations

1 site
  • Zhejiang Xiaoshan Hospital
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jun 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Feb 28, 2024
StartActual
Feb 13, 2023
Primary completionActual
Jun 15, 2023
CompletionActual
Jun 15, 2023
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06281470
Lead sponsor
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Feb 13, 2023
Primary completion
Jun 15, 2023
Completion
Jun 15, 2023
Last update
Feb 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: WS016

Start the discussion